Cabaletta Bio

Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PVâ„¢ trial evaluating rese-cel (resecabtagene autoleucel, formerly CABA-201) in patients with pemphigus vulgaris (PV) during the …

Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning Read More